A popular weight management drug, semaglutide (Wegovy) from Novo Nordisk, has been in short supply for months, leading to many individuals seeking compounded formulations. These compounded formulations are cheaper and more accessible, but come with major questions about safety and quality. A new article from MedPageToday, explores the shortage and interest in compounded formulations and includes many expert opinions on the various issues present. On the topic of patents, Professor Jacob Sherkow is quoted about how these drugs are procured and compounded by pharmacies. Specifically, Sherkow notes that Novo Nordisk's patent could pose legal issues for those creating compounded formulations, but legal recourse would be costly in terms of time and money.
Read the full article on the MedPage Today website.